Guilford Pharmaceuticals Inc. on Monday said it initiated a Phase III development program for Aquavan Injection, a candidate for procedural sedation. (BioWorld Today)

Guilford Pharmaceuticals Inc. on Monday said it initiated a Phase III development program for Aquavan Injection, a candidate for procedural sedation. (BioWorld Today)

Adolor Corp. and partner GlaxoSmithKline plc submitted the first portion of a new drug application for Entereg, a candidate for the management of postoperative ileus. (BioWorld Today)

Adolor Corp. and partner GlaxoSmithKline plc submitted the first portion of a new drug application for Entereg, a candidate for the management of postoperative ileus. (BioWorld Today)

ISTA Pharmaceuticals Inc. won FDA approval of Vitrase for use as a spreading agent to facilitate the dispersion and absorption of other drugs. Meanwhile, the firm is awaiting approval on an earlier new drug application for Vitrase as a single injection to the eye for vitreous hemorrhage. (BioWorld Today)

ISTA Pharmaceuticals Inc. won FDA approval of Vitrase for use as a spreading agent to facilitate the dispersion and absorption of other drugs. Meanwhile, the firm is awaiting approval on an earlier new drug application for Vitrase as a single injection to the eye for vitreous hemorrhage. (BioWorld Today)

GAITHERSBURG, Md. - The Oncologic Drugs Advisory Committee generally agreed that it is reasonable to ask makers of Aranesp and Procrit to conduct placebo-controlled trials to assess possible adverse events. (BioWorld Today)

GAITHERSBURG, Md. - The Oncologic Drugs Advisory Committee generally agreed that it is reasonable to ask makers of Aranesp and Procrit to conduct placebo-controlled trials to assess possible adverse events. (BioWorld Today)